Clinical Trials

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02639026 2025-11-25

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

BreastDermatologicGastrointestinalThoracic

53 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT06058663 2025-10-20

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Phase 1 Recruiting

16 enrolled

Cholangiocarcinoma

NCT03019003 2025-09-16

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Phase 1 Active not recruiting

13 enrolled 12 charts

Head & Neck

Head and Neck Neoplasms

NCT04605731 2025-09-10

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

25 enrolled

Carcinoma, Hepatocellular

NCT05701488 2025-09-02

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Phase 1 Recruiting

20 enrolled

Phase 1 Active not recruiting

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02537418 2025-08-19

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

153 enrolled

Solid Malignancies

NCT03277482 2025-05-31

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

16 enrolled

Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT06710223 2025-02-11

Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab

Phase 1 Recruiting

20 enrolled

Carcinoma, Hepatocellular

NCT03509012 2025-01-14

CLOVER

105 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT03802747 2024-12-09

Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases

Colorectal Neoplasms

NCT04287894 2024-11-06

Induction

18 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02754856 2024-10-09

Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery

24 enrolled 12 charts

Colorectal Neoplasms

NCT02762006 2024-03-18

Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

29 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02616185 2023-11-02

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

91 enrolled 51 charts

Prostatic Neoplasms

NCT02718911 2023-10-16

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

72 enrolled 23 charts

Other solid neoplasm

Solid Tumor

NCT03452332 2023-09-13

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

20 enrolled

Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT03963414 2023-08-28

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

1 enrolled

Small Cell Lung Carcinoma

NCT05928962 2023-07-10

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

Phase 1 Unknown

10 enrolled

Melanoma

NCT03275597 2023-05-15

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

17 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01975831 2022-10-12

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

BreastGastrointestinalGenitourinaryGynecologic

104 enrolled 23 charts

Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT02716805 2022-10-12

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

6 enrolled 11 charts

Plasma cell

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma

NCT03122496 2022-06-08

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

13 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT02978482 2021-08-18

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

26 enrolled

Advanced Malignancy

NCT03144778 2021-03-18

Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

39 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01938612 2021-03-12

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

GastrointestinalHead & Neck

269 enrolled

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms

NCT03089645 2020-07-27

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

39 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT04073160 2020-07-07

TRIO Bladder

Urinary Bladder Neoplasms

NCT01103635 2020-04-07

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma

25 enrolled

Melanoma

NCT02261220 2020-03-06

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

380 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT04274816 2020-02-18

Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma

13 enrolled

Melanoma

NCT03005002 2019-12-26

Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver

9 enrolled

Colorectal Neoplasms

NCT00702923 2019-11-21

CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer

12 enrolled 9 charts

Prostatic Neoplasms

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

BreastDermatologicGastrointestinalThoracic

58 enrolled

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT00880854 2019-11-15

Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer

Urinary Bladder Neoplasms

NCT02000947 2019-10-31

D4190C00006

459 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02705482 2019-08-26

A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

58 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT02868632 2019-04-05

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

Pancreatic Neoplasms

NCT02549651 2019-02-27

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

32 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02141347 2018-12-12

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Other solid neoplasmThoracic

65 enrolled

Part A and B: Advanced Solid Malignancies

NCT03085849 2018-12-10

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

2 enrolled

Small Cell Lung Carcinoma

NCT02262741 2017-10-23

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

71 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02040064 2016-06-09

GEFTREM

27 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00372853 2012-06-06

Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

28 enrolled

Carcinoma, Renal Cell

NCT00431275 2012-06-06

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

85 enrolled

Melanoma

NCT00556023 2012-06-06

A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer

37 enrolled

Pancreatic Neoplasms

NCT00585000 2012-06-06

A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma

49 enrolled